Published in Comp Immunol Microbiol Infect Dis on January 01, 1979
Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J Virol (1996) 1.67
5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J Virol (1995) 1.26
Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus. J Virol (1998) 1.23
Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates. J Virol (1999) 1.13
Strong selective pressure for evolution of an Epstein-Barr virus LMP2B homologue in the rhesus lymphocryptovirus. J Virol (1999) 0.98
Herpesvirus saimiri-induced lymphoblastoid rabbit cell line: growth characteristics, virus persistence, and oncogenic properties. J Virol (1985) 0.84
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science (1986) 8.15
Studies on the transfer of subviral infectivity from SV40-induced hamster tumor cells to indicator cells. Virology (1966) 4.16
Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes). Proc Natl Acad Sci U S A (1972) 3.89
A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med (1992) 3.42
In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med (1988) 2.81
HBLV (or HHV-6) in human cell lines. Nature (1987) 2.53
Genomic analysis of the human B-lymphotropic virus (HBLV). Science (1986) 2.23
Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature (1989) 1.96
Brain death and organ donation in a neurosurgical unit: audit of recent practice. BMJ (1990) 1.94
To resuscitate or not, that is the question. Med J Aust (1989) 1.93
Induction of cellular DNA synthesis in human leukocytes by Epstein-Barr virus. Nature (1971) 1.91
Complement-fixing antibodies in sera of human and nonhuman primates to viral antigens derived from Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (1967) 1.91
Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci U S A (1992) 1.85
Selective transformation of B lymphocytes by E.B. virus. Lancet (1973) 1.84
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
Isolated central respiratory failure due to syringomyelia and Arnold-Chiari malformation. BMJ (1988) 1.82
Studies on leukocytes growing in continuous culture derived from normal human donors. J Natl Cancer Inst (1968) 1.80
B-cell characteristics of human peripheral and cord blood lymphocytes transformed by Epstein-Barr virus. J Natl Cancer Inst (1974) 1.75
Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet (1972) 1.71
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. Cancer Genet Cytogenet (1999) 1.71
How far should we investigate and treat prostate cancer? A lawyer's perspective. Med J Aust (1994) 1.71
Herpesvirus papio DNA is similar in organization to Epstein-Barr virus DNA. J Virol (1981) 1.54
Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion (2003) 1.47
Clinical, epidemiologic, and virologic studies in four clusters of the chronic fatigue syndrome. Arch Intern Med (1992) 1.46
Confidentiality and the AMA's new code of ethics. Med J Aust (1997) 1.38
Epstein-Barr virus-induced viral and soluble complement-fixing antigens in Burkitt lymphoma cell cultures. Proc Soc Exp Biol Med (1970) 1.37
Antigens and DNA of a chimpanzee agent related to Epstein-Barr virus. J Virol (1976) 1.37
Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients. Int J Cancer (1975) 1.35
Antibody reactions to herpesvirus saimiri (HVS)-induced early and late antigens (EA and LA) in HVS-infected squirrel, marmoset and owl monkeys. Int J Cancer (1973) 1.34
Molecular studies of HHV-6. J Virol Methods (1988) 1.32
Infectious mononucleosis: complement-fixing antibodies to herpes-like virus associated with Burkitt lymphoma. Science (1968) 1.30
Diverse tropism of HBLV (human herpesvirus 6) Lancet (1987) 1.29
Biologic and antigenic characteristics of Epstein-Barr virus-related Herpesviruses of chimpanzees and baboons. Int J Cancer (1977) 1.29
Epstein-Barr virus-associated antigens activated in human cells by 5-bromodeoxyuridine. Proc Soc Exp Biol Med (1972) 1.26
In vitro stimulation of human lymphocytes by Epstein-Barr virus. Cell Immunol (1972) 1.26
Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer (1971) 1.25
DNA of herpesvirus pan, a third member of the Epstein-Barr virus-Herpesvirus papio group. J Virol (1982) 1.24
The spectrum of clinical and laboratory findings resulting from human herpesvirus-6 (HHV-6) in patients with mononucleosis-like illnesses not resulting from Epstein-Barr virus or cytomegalovirus. Am J Clin Pathol (1990) 1.23
Human herpesvirus 7 (HHV-7) strain JI: independent confirmation of HHV-7. J Infect Dis (1992) 1.22
Immunoferritin and immunofluorescent studies with Epstein-Barr virus and herpes simplex virus by use of human sera and hyperimmune rabbit sera. J Natl Cancer Inst (1970) 1.19
Antigenic relationships among human herpesvirus-6 isolates. J Med Virol (1992) 1.18
Identification of the human herpesvirus 6 glycoprotein H and putative large tegument protein genes. J Virol (1991) 1.17
Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B cell lymphoma tissues of three patients. Leukemia (1988) 1.17
Preparation of immune rabbit sera with neutralizing activity against human cytomegalovirus and varicella-zoster virus. J Gen Virol (1970) 1.15
Symptomatology of late-life minor depression among primary care patients. Psychosomatics (1990) 1.15
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis (1994) 1.14
Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol (1999) 1.14
Molecular cloning and expression of alternatively spliced PITSLRE protein kinase isoforms. J Biol Chem (1994) 1.13
Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol (1991) 1.11
Modulatory effects of Epstein-Barr, herpes simplex, and human herpes-6 viral infections and coinfections on cytokine synthesis. A comparative study. J Immunol (1992) 1.09
Malignant lymphoma with lymphocytic leukemia induced in owl monkeys by Herpesvirus saimiri. J Natl Cancer Inst (1971) 1.08
Comparative studies of Epstein-Barr virus strains from Ghana and the United States. Int J Cancer (1976) 1.07
HTLV-III infection of EBV-genome-positive B-lymphoid cells with or without detectable T4 antigens. Int J Cancer (1987) 1.07
Determination of the disulphide bonding pattern in proteins by local and global analysis of nuclear magnetic resonance data. Application to flavoridin. J Mol Biol (1993) 1.06
Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol (1993) 1.06
HHV-6 reactivation in chronic fatigue syndrome. Lancet (1991) 1.06
A repeat sequence, GGGTTA, is shared by DNA of human herpesvirus 6 and Marek's disease virus. J Virol (1988) 1.05
Ectopic gonadotropin production before clinical recognition of bronchogenic carcinoma. N Engl J Med (1968) 1.05
Human herpesvirus 6 (HHV6) and chronic fatigue syndrome (CFS). Can Dis Wkly Rep (1991) 1.05
Association of EB-virus infection with the post-perfusion syndrome. Lancet (1969) 1.05
Latent herpesvirus-6 in salivary and bronchial glands. Lancet (1990) 1.03
Differentiation of cross-reacting simian cytomegalovirus strains by late 19S rabbit neutralizing antibodies. J Immunol (1969) 1.02
HL-A antigens of human lymphoid cells in long-term tissue culture. Transplantation (1969) 1.00
Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression. J Virol (1994) 1.00
Antibody prevalence to HBLV (human herpesvirus-6, HHV-6) and suggestive pathogenicity in the general population and in patients with immune deficiency syndromes. J Virol Methods (1988) 0.99
Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA (1988) 0.98
NIH clinical staff conference. Burkitt's tumor. Ann Intern Med (1969) 0.98
Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity. Am J Med (1967) 0.98
The incidence of complement-fixing antibodies to herpes simplex and herpes-like viruses in man and rhesus monkeys. Proc Soc Exp Biol Med (1968) 0.98
Leukocyte transforming agent (Epstein-Barr virus) in newborn infants and older individuals. J Pediatr (1976) 0.96
Attempts to transmit infectious mononucleosis to rhesus monkeys and marmosets and to isolate herpes-like virus. Proc Soc Exp Biol Med (1969) 0.95
Patterns of antibodies to SV40 in children following the last booster with inactivated poliomyelitis vaccines. Proc Soc Exp Biol Med (1967) 0.94
Murine cytomegalovirus: induction of and sensitivity to interferon in vitro. Infect Immun (1975) 0.93
Murine leukemia viruses: rupture with ether and detergents to subviral constituents. Natl Cancer Inst Monogr (1966) 0.93
Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome Res (1998) 0.93
Cellular immunity in infectious mononucleosis. II. Specific reactivity to Epstein-Barr Virus antigens and correlation with clinical and hematologic parameters. J Immunol (1978) 0.92
Preparation of rabbit immune serum with neutralizing activity against a simian cytomegalovirus (SA6). J Immunol (1969) 0.92
Morphological studies on Herpesvirus saimiri in subhuman and human cell cultures. Cancer Res (1971) 0.92
[Humidifier lung]. Schweiz Med Wochenschr (1981) 0.92
Human B-lymphotropic virus in Germany. Lancet (1987) 0.92
Mixed culture cytopathogenicity induced by virus preparations derived from cultures infected by simian sarcoma virus. J Natl Cancer Inst (1972) 0.91
Relationship of Epstein-Barr virus-induced membrane antigens in lymphoid cells to viral envelope antigens. J Immunol (1970) 0.91
Comparison of the Raji cell line fluorescent antibody to membrane antigen test and the enzyme-linked immunosorbent assay for determination of immunity to varicella-zoster virus. J Clin Microbiol (1982) 0.90
Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study. J Med Virol (2000) 0.89
The Inoue-Melnick virus, human herpesvirus type 6, and the chronic fatigue syndrome. Ann Intern Med (1989) 0.89
Effects of 5-tungsto-2-antimoniate in oncogenic DNA and RNA virus-cell systems. Eur J Cancer (1977) 0.89
Macroglossia and posterior fossa disease. Anaesthesia (1988) 0.89
Human herpesvirus type 8 in salivary gland tumors. J Clin Virol (2000) 0.88
Active human herpesvirus-6 (HHV-6) infection associated with Kikuchi-Fujimoto disease and systemic lupus erythematosus (SLE). In Vivo (1991) 0.88
Characteristics of Herpesvirus saimiri-induced lymphoma cells in tissue culture. In Vitro (1974) 0.88
Experimental infection of Callithrix Jacchus marmosets with Herpesvirus ateles, Herpesvirus saimiri, and Epstein Barr virus. Biomedicine (1978) 0.88
Superoxide generation and its modulation by adenosine in the neutrophils of subjects with asthma. J Allergy Clin Immunol (1989) 0.87
Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. J Natl Cancer Inst (1980) 0.87
Retention of Teflon particles in hamster lungs: a stereological study. J Aerosol Med (2000) 0.87
In vitro inhibition of human herpesvirus-6 by phosphonoformate. J Virol Methods (1988) 0.87
Functional hypoglycemia in early latent diabetes. Ann N Y Acad Sci (1968) 0.87
Persistent active herpes virus infection associated with atypical polyclonal lymphoproliferation (APL) and malignant lymphoma. Anticancer Res (1990) 0.87
Human herpesvirus-6 and cross-reactivity with other herpesviruses. Lancet (1989) 0.86